Order Article Reprints

Casiraghi A, Longhena F, Faustini G, Ribaudo G, Suigo L, Camacho-Hernandez GA, Bono F, Brembati V, Newman AH, Gianoncelli A, et al. Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice. Pharmaceutics. 2022; 14(8):1595. https://doi.org/10.3390/pharmaceutics14081595

Casiraghi, Andrea, Francesca Longhena, Gaia Faustini, Giovanni Ribaudo, Lorenzo Suigo, Gisela Andrea Camacho-Hernandez, Federica Bono, Viviana Brembati, Amy Hauck Newman, Alessandra Gianoncelli, and et al. 2022. "Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice" Pharmaceutics 14, no. 8: 1595. https://doi.org/10.3390/pharmaceutics14081595

Casiraghi, A., Longhena, F., Faustini, G., Ribaudo, G., Suigo, L., Camacho-Hernandez, G. A., Bono, F., Brembati, V., Newman, A. H., Gianoncelli, A., Straniero, V., Bellucci, A., & Valoti, E. (2022). Methylphenidate Analogues as a New Class of Potential Disease-Modifying Agents for Parkinson’s Disease: Evidence from Cell Models and Alpha-Synuclein Transgenic Mice. Pharmaceutics, 14(8), 1595. https://doi.org/10.3390/pharmaceutics14081595